Knight Therapeutics (TSE:GUD) has released an update.
Knight Therapeutics Inc. successfully concluded its Annual General Meeting, with all director nominees from the Management Information Circular being elected with high approval rates. Additionally, Ernst & Young LLP were appointed as external auditors with overwhelming shareholder support, and a resolution to renew unallocated rights under the Omnibus Equity Incentive Plan was approved by a significant majority.
For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.
